Wedbush Reiterates $43.00 Price Target for NPS Pharmaceuticals (NPSP)
Stock analysts at Wedbush set a $43.00 price target on shares of NPS Pharmaceuticals (NASDAQ:NPSP) stock in a report issued on Thursday, Analyst Ratings.Net reports. Wedbush’s price target indicates a potential upside of 28.78% from the stock’s previous close.
A number of other firms have also recently commented on NPSP. Analysts at Bank of America Corp. initiated coverage on shares of NPS Pharmaceuticals (NASDAQ:NPSP) in a research note to investors on Thursday. They set a “buy” rating and a $46.00 price target on the stock. Separately, analysts at Oppenheimer raised their price target on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $28.00 to $39.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of NPS Pharmaceuticals (NASDAQ:NPSP) to $47.00 in a research note to investors on Thursday, September 26th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $32.86.
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) traded up 4.60% on Thursday, hitting $34.925. The stock had a trading volume of 859,884 shares. NPS Pharmaceuticals has a one year low of $7.35 and a one year high of $34.00. The stock has a 50-day moving average of $27.60 and a 200-day moving average of $18.05. The company’s market cap is $3.542 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.06. The company had revenue of $36.50 million for the quarter, compared to the consensus estimate of $31.62 million. During the same quarter last year, the company posted $0.08 earnings per share. NPS Pharmaceuticals’s revenue was down 31.8% compared to the same quarter last year. Analysts expect that NPS Pharmaceuticals will post $-0.20 EPS for the current fiscal year.
In other NPS Pharmaceuticals news, CFO Luke Beshar sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $30.26, for a total value of $1,513,000.00. Following the sale, the chief financial officer now directly owns 59,180 shares of the company’s stock, valued at approximately $1,790,787. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.